TCRR - TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity

TCR2 Therapeutics (TCRR) has established a manufacturing partnership with ElevateBio, to leverage the extensive technical capabilities at ElevateBio BaseCamp, a cell and gene therapy manufacturing facility based in Waltham, MA. The partnership will focus on the production of TC-210, TCR2’s TRuC-T cell targeting advanced mesothelin-expressing cancer, to support demand for the anticipated Phase 2 clinical trial. The BaseCamp partnership enables TCR2 to establish additional manufacturing capacity and technical capabilities in the U.S., in addition to its existing Stevenage, UK, manufacturing facility.

For further details see:

TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity